Entrada Therapeutics, Inc. (TRDA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 11, 2025, discloses the results of the Company's 2025 Annual Meeting of Stockholders. The meeting was held in a virtual-only format. As of the record date (April 14, 2025), there were 37,953,417 shares of Common Stock outstanding. A quorum was established with 30,259,526 shares present or represented by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on two proposals, both of which were approved:
- Proposal No. 1 (Election of Directors): Three Class I director nominees were elected to serve until the 2028 annual meeting.
- Dipal Doshi: 27,809,399 For; 429,248 Withheld; 2,020,879 Broker Non-Votes.
- Kush M. Parmar, M.D., Ph.D.: 24,883,797 For; 3,354,850 Withheld; 2,020,879 Broker Non-Votes.
- Mary Thistle: 27,768,093 For; 470,554 Withheld; 2,020,879 Broker Non-Votes.
- Proposal No. 2 (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
- Results: 30,176,125 For; 74,925 Against; 8,476 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of the voting outcomes.
Investor Verification Checklist
- Verify the final composition of the Board of Directors following the election of the three Class I nominees.
- Confirm the engagement of Ernst & Young LLP for the 2025 fiscal year audit.
- Review the definitive Proxy Statement filed on April 25, 2025, for detailed biographies of the elected directors and further context on the proposals.
- Monitor upcoming financial filings (10-K or 10-Q) for the first disclosure of financial performance metrics, as none are included in this 8-K.